BMSC-derived exosomal ANTXR1 inhibits erythroid differentiation by suppressing the TLR4/MyD88/NF-κB signaling pathway Authors: Dengyun Chen, Liping Lin, Yibo Wu, Kunbo Huang, Hanhui Zhang, Qingqing Chen Published: 2026 ABSTRACT Aplastic anemia (AA) is a bone marrow failure syndrome characterized by impaired hematopoiesis and a dysfunctional marrow microenvironment. Bone marrow-derived mesenchymal stem cell (BMSC)-derived exosomes play a crucial role in intercellular communication; however, the role of exosomal anthrax toxin receptor 1 (ANTXR1) in erythroid differentiation remains unclear. Mouse BMSCs were isolated, characterized, and transfected with either ANTXR1-overexpressing or ANTXR1-silencing lentiviral vectors. Exosomes were collected and identified using transmission electron microscopy, nanoparticle tracking analysis, and exosomal marker detection. K562 cells and human cord blood CD34⁺cells were treated with these exosomes. Erythroid differentiation was evaluated through flow cytometry for CD235a and CD71, benzidine staining, RT-qPCR, and Western blot analysis of GATA1 and ALAS2. Apoptosis and inflammatory signaling were examined using flow cytometry, ELISA, Western blotting, and co-immunoprecipitation. TLR4 inhibitor and agonist treatments were applied to verify pathway involvement. BMSC-derived exosomes successfully carried ANTXR1, and their abundance reflected ANTXR1 expression in donor BMSCs. Exosomes enriched in ANTXR1 inhibited erythroid differentiation, as evidenced by reduced CD235a/CD71 expression, decreased GATA1 and ALAS2 levels, and diminished hemoglobin synthesis. In contrast, ANTXR1-deficient exosomes promoted erythroid differentiation and apoptosis while activating the TLR4/MyD88/NF-κB pathway. Pharmacological inhibition of TLR4 attenuated these effects, whereas TLR4 agonist treatment enhanced them. Co-immunoprecipitation further supported an interaction between ANTXR1 and TLR4. BMSC-derived exosomal ANTXR1 suppresses erythroid differentiation, at least in part, by modulating the TLR4/MyD88/NF-κB signaling pathway. These findings identify exosomal ANTXR1 as a potential regulator of erythropoiesis.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-47662-9. Introduction Aplastic anemia (AA) is an acquired hematological disease defined by bone marrow failure and its cardinal features of pancytopenia and a hypocellular bone marrow1–3. The etiology of AA is multifactorial, with links to viral infections, various drugs, and autoimmune disorders. The pathogenesis of the disease is primarily understood to involve three key mechanisms: immune-mediated destruction of hematopoietic stem and progenitor cells, intrinsic hematopoietic stem cell defects, and abnormalities within the bone marrow microenvironment4,5. The mainstay treatments for AA currently consist of hematopoietic stem cell transplantation (HSCT), immunosuppressive therapy (IST), supportive care, and various drug therapies. Nevertheless, each of these approaches is subject to significant limitations. HSCT carries the risk of immune rejection, while IST is often complicated by high rates of relapse and requires long-term administration. Furthermore, androgen therapy is limited by its potential for hepatotoxicity, and blood transfusions serve only as a palliative measure for rapid anemia correction6–8. Consequently, the exploration of new therapeutic pathways for AA remains a critical imperative. Bone marrow-derived mesenchymal stem cells (BMSCs) represent a population of multipotent adult stem cells found in abundance within the stromal connective tissue of the bone marrow. The exosomes released by these cells are critical mediators in a range of physiological and pathological processes, with functions spanning tissue repair, immune regulation, and anti-inflammation9,10. Specifically in the field of bone regeneration, exosomes derived from BMSCs exhibit high therapeutic potential; their beneficial effects on cartilage damage and bone loss have been documented in numerous reports11,12. In terms of immunomodulation, BMSC-derived exosomes have been shown to attenuate the polarization of macrophages and microglia, leading to a subsequent decrease in pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and an increase in the anti-inflammatory cytokine IL-1013,14. Such dysregulated immune activation promotes a direct assault on hematopoietic stem cells (HSCs) by pro-inflammatory cytokines, which induces HSC apoptosis or functional suppression and damages the bone marrow microenvironment15. Thus, exosomes originating from BMSCs play a pivotal immunomodulatory role within the bone marrow microenvironment. Anthrax toxin receptor 1 (ANTXR1) is a type I single-pass transmembrane protein of the ATR family, which is characterized by a von Willebrand factor A (vWA) domain that enables direct binding to the protective antigen (PA) component of the anthrax toxin16. In addition to its function as the principal receptor mediating toxin internalization, ANTXR1 has recently been identified as being highly expressed on tumor vascular endothelial cells, contributing to pathological angiogenesis17. Moreover, ANTXR1 possesses functions related to inducing the secretion of immunosuppressive factors, promoting the polarization of M2 macrophages, and driving T cell exhaustion18. Research has demonstrated that ANTXR1 regulates chondrogenic differentiation through the GSK3β/β-catenin and Smad2/Smad4 signaling pathways, exerting a chondrogenic effect during the mechanical stimulation of BMSCs19. Additionally, in individuals with β-thalassemia, polymorphisms in the ANTXR1 gene are closely linked to fetal hemoglobin (HbF) levels20. This finding implicates ANTXR1 as a potential therapeutic target for the treatment of aplastic anemia. Separately, the activation of TLR4 drives splenic stress erythropoiesis (also known as extramedullary erythropoiesis) by upregulating inflammatory cytokines like Granulocyte-Colony Stimulating Factor (G-CSF), in response to feedback from hypoxia and erythropoietin (EPO). This process may also involve synergistic effects from other TLRs, such as TLR7 and TLR921,22. In summary, BMSC-derived exosomes show therapeutic potential for aplastic anemia, and ANTXR1 is a potential regulator of erythroid differentiation. However, the precise role of exosomal ANTXR1 in erythroid differentiation and its relationship with inflammatory signaling pathways such as TLR4 remain unclear. This study aims to elucidate the capacity of BMSC-derived exosomes to regulate the erythroid differentiation of K562 cells via their ANTXR1 cargo. Furthermore, we will investigate whether this process is dependent on the TLR4/MyD88/NF-κB signaling pathway. The results are intended to provide an experimental basis for developing novel therapeutic strategies for AA. Materials and methods Animal and ethics statement Male C57BL/6 mice (6–8 weeks old) were obtained fromSPF (Beijing) Biotechnology Co., Ltd. All animal housing and experimental procedures were conducted in strict accordance with the Guidelines for the Care and Use of Laboratory Animals and were approved by the Experimental Animal Ethics Committee of Quanzhou Medical College (Approval No. 2024049). During the study, the mice were housed under controlled conditions of temperature (20–25 °C), humidity (40–60%), and a 12-hour light/dark cycle, with ad libitum access to food and water. At the end of the experiment, all mice were anesthetized with an intraperitoneal injection of sodium pentobarbital (50 mg/kg) and subsequently euthanized by cervical dislocation. Isolation and characterization of mouse BMSCs BMSCs were isolated from the femurs and tibias of mice using the whole bone marrow flushing method. The isolated cells were seeded in high-glucose Dulbecco’s Modified Eagle Medium (DMEM, Gibco, 11965092) containing 10% exosome-depleted fetal bovine serum (ED-FBS, System Biosciences, EXO-FBS-50 A-1) and cultured in a humidified incubator at 37 °C with 5% CO2. The medium was first changed 48 h after seeding, with subsequent changes every three days. At passage 5, the cells were characterized by flow cytometry. The expression of BMSC surface markers CD29 (Biolegend, 102216), CD90 (Biolegend, 105328), CD34 (Invitrogen, MA5-16927), and CD45 (Biolegend, 147710) was assessed, and identification was considered successful if the population was over 90% positive for CD29 and CD90 and under 5% for CD34 and CD45. BMSC culture and transfection Successfully identified BMSCs were expanded for subsequent experiments, with the passage number controlled to be within 10. Cells were seeded in 10 cm culture dishes (Corning, 430167). Upon reaching 70–80% confluency, they were transfected with recombinant lentiviral plasmids carrying either a gene-silencing sequence for ANTXR1 (sh-ANTXR1) or a gene-overexpression sequence for ANTXR1 (OE-ANTXR1), along with their corresponding negative control plasmids (sh-NC or OE-NC). Lentiviral plasmids and transfection reagents were obtained from Santa Cruz Biotechnology. After 48 h, transfection efficiency was verified by RT-qPCR and Western Blot. The cells were then divided into four groups: sh-NC, sh-ANTXR1, OE-NC, and OE-ANTXR1. Subsequently, the medium for each group was replaced with medium containing 10% ED-FBS, and the cells were cultured for an additional 48 h to collect the exosome-rich supernatant. Isolation and characterization of BMSC-derived exosomes Exosomes were extracted from the conditioned medium of each group via ultracentrifugation. The collected supernatant underwent a series of differential centrifugations: 400 × g for 10 min to remove cells; 2,000 × g for 20 min to remove dead cells and debris; and 10,000 × g for 30 min to remove large vesicles and apoptotic bodies. The supernatant was then filtered through a 0.45 μm filter (Haote, FPV403030), transferred to ultracentrifuge tubes, and centrifuged at 100,000-120,000 × g for over 70 min at 4 °C. The pellet was resuspended in PBS and washed by a second ultracentrifugation step for purification. The final pellet was resuspended in a suitable volume of PBS. The morphology of the exosomes was observed by transmission electron microscopy (TEM, Hitachi, HT-7700) to confirm their typical cup-shaped or spherical vesicle structure. Western blot was used to detect the expression of exosomal protein markers, including CD9, CD63, and Alix, and the target protein ANTXR1 to identify exosome purity and changes in ANTXR1 content. NTA analysis of exosome particle size Resuspend the exosomes in PBS and dilute the suspension. Use a particle size analyzer to observe and image the exosomes and vesicles with diameters ranging from 50 to 1,000 nm in real time. Employ software to analyze the particle size and concentration of the exosomes. Exosome sample potentiometric analysis Thaw the frozen sample in a 37 °C water bath, then place it on ice. Dilute the exosome sample with pure water and use it directly for potentiometric detection. Exosome uptake Label the exosomes using the BeyoExo™ Exosome Labeling and Tracing Kit (PKH67) (C3635M) and perform ANTXR1 protein labeling to achieve green fluorescence. Incubate red blood cells with the labeled exosomes in an incubator for 24 h. After incubation, collect the cells, wash them with PBS, and analyze exosome uptake via flow cytometry. K562 cell/human cord blood CD34⁺ cells culture and treatment The human erythroleukemia cell line K562 (Cyagen Biosciences (Suzhou) Inc., H3-0301) was cultured in RPMI-1640 medium (Corning, 10-040-CV) supplemented with 10% fetal bovine serum (FBS, Gibco,10099141) and 1% penicillin-streptomycin solution (Gibco, 15140122). Human Cord Blood CD34⁺ Cells (2 C-101) are provided by Beijing ZEPING Bioscience&Technology Co.Ltd. and are cultured in Hematopoietic Progenitor Growth Medium (PT-3926). The cells were maintained in a standard humidified incubator at 37 °C with an atmosphere of 5% CO2. For the experiments, cells were seeded into culture plates at an appropriate density and allowed to grow for 24 h before treatment. The cells were then divided into different experimental groups. In the first set of experiments, the groups were as follows: a Control group (treated with an equal volume of fresh medium), a BMSCs exo group (treated with exosomes from unmodified BMSCs), a sh-NC BMSCs exo group (treated with exosomes from BMSCs transfected with a negative control shRNA), a sh-ANTXR1 exo group (treated with exosomes from ANTXR1-silenced BMSCs), an OE-NC BMSCs exo group (treated with exosomes from BMSCs transfected with a negative control overexpression vector), and an OE-ANTXR1 exo group (treated with exosomes from ANTXR1-overexpressing BMSCs). Cells were treated with exosomes at a concentration of 1 × 10⁸ particles/mL. The second and third sets of experiments were designed to investigate the role of the TLR4 pathway. The second treatment group: a Control group, a BMSCs exo group, a sh-NC BMSCs exo group, a sh-ANTXR1 exo group, and a combination treatment group of sh-ANTXR1 exo and Stepharine (a TLR4 inhibitor, MedChemExpress, HY-N9347). Third treatment group: sh-NC BMSC exosomes, sh-ANTXR1 BMSC exosomes, MPLA (a TLR4 agonist, MedChemExpress, HY-W782032), and the combined treatment of sh-ANTXR1 exosomes with MPLA. For all treatments, exosomes were added to the cell culture medium at a predetermined concentration. Following treatment, the cells were incubated for the specified duration before being harvested for subsequent molecular and cellular analyses. Cell viability assay To quantitatively assess the effect of exosome treatments on cell proliferation over time, a Cell Counting Kit-8 (CCK-8, Vazyme, A311-01) assay was performed. K562 and CD34⁺ Cells were seeded into 96-well plates at an appropriate density and allowed to acclimate overnight. Subsequently, the cells were treated with the different exosome preparations as previously described. Following the initial treatment, the plates were incubated, and cell viability was measured at three separate time points: 24, 48, and 72 h. At each designated time point, 10 µL of CCK-8 solution was added to each well, and the plates were returned to the incubator for an additional 2 h at 37 °C. The optical density was then measured at a wavelength of 450 nm using a microplate reader. Flow cytometry analysis For the immunophenotypic characterization of the primary cells, BMSCs were harvested and washed with PBS. The cells were then incubated with fluorochrome-conjugated monoclonal antibodies specific for the murine surface antigens CD29 (Biolegend, 102216), CD90 (Biolegend, 105328), CD34 (Invitrogen, MA5-16927), and CD45 (Biolegend, 147710) for 30 min at 4 °C in the dark. After incubation, the cells were washed to remove unbound antibodies and analyzed on a flow cytometer. The cultured cells were considered successfully identified as BMSCs if the cell population demonstrated over 90% expression for the positive markers CD29, and CD90, while being negative for the hematopoietic lineage markers CD34 and CD45. To evaluate erythroid differentiation, K562 and CD34⁺ Cells from the various treatment groups were harvested, washed with PBS, and incubated with fluorescently-conjugated antibodies against the erythroid markers CD235a (BioLegend, 349106) and CD71 (Transferrin Receptor, 334108). The percentage of positive cells was subsequently determined by flow cytometric analysis. For the analysis of apoptosis, K562 cells were collected after treatment and stained using an Annexin V-FITC/Propidium Iodide (PI) Apoptosis Detection Kit (BD Biosciences, 556547). The stained cells were promptly analyzed on a flow cytometer to quantify the proportion of apoptotic cells. Enzyme-linked immunosorbent assay (ELISA) To investigate the effect of exosome treatment on the inflammatory factors, culture supernatants from treated K562 and CD34⁺ Cells were collected. The concentrations of key cytokines-IL-1β (CUSABIO, MM-0181H2), IL-10 (CUSABIO, MM-0066H2), TNF-α (CUSABIO, MM-0122H2), and the hematopoietic inhibitor TGF-β (CUSABIO, MM-0090H2) were quantitatively determined using commercial ELISA kits according to the manufacturer’s instructions. RT-qPCR To determine the effects of exosome treatment on gene expression, total RNA was extracted from K562 and CD34⁺ Cells following their respective treatments. Total RNA was extracted from cells using a commercial RNA isolation reagent (Invitrogen, 15596026). The RNA was then reverse-transcribed into cDNA using a reverse transcription kit (Vazyme, R323-01). qRT-PCR was performed on a real-time PCR system using a SYBR Green master mix (Bio-Rad, 1725121). The relative expression of target genes (ANTXR1, GATA1, ALAS2) was calculated using the 2-ΔΔCt method, with GAPDH gene serving as the internal control. Western blot Total protein was extracted from K562 or CD34⁺ Cells and exosomes using RIPA lysis buffer (Beyotime, P0013B). Protein concentration was determined using a BCA protein assay kit (Pierce, 23225). Equal amounts of protein were separated by SDS-PAGE (Epizyme, LK407-20) and transferred onto polyvinylidene fluoride (PVDF, Merck, IPVH00010) membranes. The membranes were blocked with 5% non-fat milk and then incubated overnight at 4 °C with primary antibodies against ANTXR1 (Proteintech, 15091-1-AP, 1:800), CD9 (Proteintech, 205971-1-AP, 1:1000), CD63 (Proteintech, 25682-1-AP, 1:1000), Alix (Proteintech, 67715-1-AP, 1:1000), GATA1 (Proteintech, 10917-1-AP, 1:1000), ALAS2 (Proteintech, 68332-1-lg, 1:1200), TLR4 (Proteintech, 1911-1-AP, 1:3000), MyD88 (Proteintech, 23230-1-AP, 1:3000), p65 (Proteintech, 66535-1-Ig, 1:3000), p-p65 (Proteintech, 82335-1-RR, 1:5000), and β-actin (Proteintech, 20536-1-AP, 1:5000). After washing, the membranes were incubated with HRP-conjugated secondary antibodies (Proteintech, 2SA00001-2, 1:10000). Protein bands were visualized using an enhanced chemiluminescence (ECL) detection system. Co-immunoprecipitation (Co-IP) Add ANTXR1- or TLR4-specific antibodies to the protein lysate, using isotype-matched IgG as a negative control. Incubate overnight at 4 °C with gentle rotation. The following day, add Protein A/G magnetic beads (Thermo Fisher) and incubate at 4 °C for 2 h. Wash the beads with pre-chilled lysis buffer to remove non-specifically bound proteins. Perform Western blot analysis on the immunoprecipitated complexes using ANTXR1 and TLR4 antibodies, respectively. Benzidine staining To functionally confirm the induction of erythroid differentiation, hemoglobin synthesis in K562 and CD34⁺ Cells was evaluated by benzidine staining. Following treatment with the various exosome preparations, the K562 and CD34⁺ Cells were harvested and washed with PBS. The cell pellet was then stained with a freshly prepared benzidine solution containing hydrogen peroxide (Sigma-Aldrich, 33–1 A). After colorimetric reaction, the cells were observed under a light microscope. The peroxidase active site is stained brown. Statistical analysis All experiments were performed at least three times, and the data are presented as the mean ± standard deviation (SD). Statistical analyses were performed using appropriate statistical software GraphPad Prism 10.2.0. Comparisons between two groups were made using a Student’s t-test, while comparisons among multiple groups were performed using one-way analysis of variance (ANOVA). A p value of less than 0.05 was considered statistically significant. Significance levels are indicated as *p < 0.05, **p < 0.01, and ***p < 0.001. Results Isolation and validation of exosomes To obtain qualified exosomes, we first isolated and identified BMSCs from mice, positive markers CD29, and CD90 as, CD34 and CD45 as negative marker (Fig. 1A). These BMSCs were then transfected with recombinant lentiviral plasmids designed to either silence or overexpress ANTXR1, along with their respective control plasmids. The efficiency of transfection was confirmed by Western Blot and qRT-PCR. The results indicated significant changes in both protein and mRNA levels of ANTXR1 following knockdown and overexpression. Specifically, overexpression of ANTXR1 led to a significant increase in its protein and mRNA levels in mouse BMSCs (Fig. 1B,D). Conversely, silencing of ANTXR1 resulted in a marked decrease in its protein and gene expression (Fig. 1C,E). Subsequently, exosomes were extracted from these cultured cells. The morphology of the isolated exosomes was observed using transmission electron microscopy (TEM), which revealed that they were intact and spherical in shape (Fig. 1F). Results from nanoparticle tracking analysis (NTA) and zeta potential measurements indicated that the vesicle particle size was primarily within the 60–100 nm range, aligning perfectly with the typical size profile of exosomes (Fig. 1G–H). Furthermore, we examined the expression of exosomal protein markers CD9, CD63, and Alix as well as the ANTXR1 protein. As shown in the results in Fig. 1G, CD63, CD9, and Alix were positively expressed in the vesicles isolated from each group, with no significant differences in expression among the groups. This is consistent with the molecular characteristics of exosomes (Fig. 1I). Crucially, the expression of ANTXR1 in the exosomes correlated with its expression in the parent cells. Overexpression of ANTXR1 in BMSCs led to an increased level of ANTXR1 in the secreted exosomes, while silencing ANTXR1 in the cells resulted in a decreased amount of ANTXR1 carried by the exosomes (Fig. 1J). This demonstrates that exosomes can carry ANTXR1 and that the quantity of exosomal ANTXR1 is influenced by the expression level in the host cell. Fig. 1Exosomes derived from BMSCs carry ANTXR1. (A) BMSCs marker detection includes CD29, CD34, CD44, CD45 and CD90. (B, C) Representative Western Blot images and quantitative analysis of ANTXR1 protein levels in mouse BMSCs following transfection with (B) ANTXR1 overexpression (OE-ANTXR1) or (C) ANTXR1 silencing (sh-ANTXR1) lentiviral plasmids and their respective controls. (D, E) Bar charts showing the mRNA expression of ANTXR1 in mouse BMSCs after transfection with plasmids for (D) ANTXR1 overexpression or (E) ANTXR1 silencing, as determined by qRT-PCR. (F) Representative TEM image of isolated exosomes, showing their typical spherical morphology. Scale bar, 100 nm. Potential analysis of exosome samples (G) and particle size analysis of exosome samples (H) are presented. (I) Western Blot analysis confirming the presence of ANTXR1 and the exosomal markers CD9, CD63, and Alix in purified exosomes. (J) Quantitative analysis of ANTXR1 protein levels in exosomes, normalized to the exosomal marker CD63, from the different treatment groups. Data are presented as mean ± SD. Statistical significance is indicated as follows: *p < 0.05, **p < 0.01, ***p < 0.001. Exosomes derived from BMSCs carry ANTXR1. (A) BMSCs marker detection includes CD29, CD34, CD44, CD45 and CD90. (B, C) Representative Western Blot images and quantitative analysis of ANTXR1 protein levels in mouse BMSCs following transfection with (B) ANTXR1 overexpression (OE-ANTXR1) or (C) ANTXR1 silencing (sh-ANTXR1) lentiviral plasmids and their respective controls. (D, E) Bar charts showing the mRNA expression of ANTXR1 in mouse BMSCs after transfection with plasmids for (D) ANTXR1 overexpression or (E) ANTXR1 silencing, as determined by qRT-PCR. (F) Representative TEM image of isolated exosomes, showing their typical spherical morphology. Scale bar, 100 nm. Potential analysis of exosome samples (G) and particle size analysis of exosome samples (H) are presented. (I) Western Blot analysis confirming the presence of ANTXR1 and the exosomal markers CD9, CD63, and Alix in purified exosomes. (J) Quantitative analysis of ANTXR1 protein levels in exosomes, normalized to the exosomal marker CD63, from the different treatment groups. Data are presented as mean ± SD. Statistical significance is indicated as follows: *p < 0.05, **p < 0.01, ***p < 0.001. Exosomal ANTXR1 inhibits erythroid differentiation of K562 cells To determine the optimal treatment duration, K562 cells were treated with exosomes for 24, 48, and 72 h. Consistent with our hypothesis that ANTXR1 promotes proliferation, exosomes from ANTXR1-overexpressing BMSCs (OE-ANTXR1 exo) significantly increased the viability of K562 cells in a time-dependent manner. In contrast, exosomes from ANTXR1-silenced BMSCs (sh-ANTXR1 exo) suppressed cell viability (Fig. 2A), which aligns with its role in promoting differentiation. The 48-hour time point was selected for subsequent experiments to ensure a clear distinction in differentiation markers. Next, K562 cells were treated with exosomes derived from ANTXR1-overexpressing and ANTXR1-silenced BMSCs. The expression of key erythroid differentiation markers was subsequently evaluated. The results revealed that in the K562 cell line, sh-ANTXR1 exo significantly upregulated the expression of erythroid markers CD235a and CD71. Conversely, OE-ANTXR1 exo led to a significant downregulation of these markers (Fig. 2B–E). GATA1 is the master transcriptional regulator of erythropoiesis, activating globin and anti-apoptotic genes23. A critical downstream target of GATA1 is ALAS2, the rate-limiting enzyme for heme biosynthesis, which establishes a positive feedback loop crucial for differentiation24,25. Following treatment of K562 cells, a significant upregulation of GATA1 and ALAS2 at both the protein and transcript levels was observed after exposure to sh-ANTXR1 exo. Conversely, their expression was downregulated by OE-ANTXR1 exo (Fig. 2F-J). To functionally corroborate these molecular changes, hemoglobin synthesis was assessed via benzidine staining. Consistent with the expression data, the percentage of benzidine-positive cells was markedly increased by sh-ANTXR1 exo but was decreased by those from ANTXR1-overexpressing cells, confirming that exosomal ANTXR1 inhibits hemoglobin production (Fig. 2K). The results for CD34+ cells align with those for K562; refer to Supplementary Fig. 1. Fig. 2Exosomes from ANTXR1-overexpressing or silenced BMSCs regulate the erythroid differentiation of K562 cells. (A) CCK8 showed the effect of exosome processing time (24, 48, and 72 h) on cell viability. (B, C) Quantitative bar charts of the flow cytometry data, showing the percentage of CD235a + and CD71 + cells in the K562 population, respectively. (D, E) Representative flow cytometry gating plots showing the expression of erythroid differentiation markers CD235a and CD71 on the surface of K562 cells after treatment with exosomes from ANTXR1-overexpressing or silenced BMSCs. (F) Western blot analysis of GATA1 and ALAS2 protein expression. (G, H) Quantification of the relative protein expression of GATA1 and ALAS2, respectively. (I, J)Relative mRNA expression of GATA1 and ALAS2 determined by qRT-PCR. (K) Quantification of the percentage of benzidine-positive cells. Data are presented as mean ± SD. Statistical significance is indicated as follows: *p < 0.05, **p < 0.01.***p < 0.001. Exosomes from ANTXR1-overexpressing or silenced BMSCs regulate the erythroid differentiation of K562 cells. (A) CCK8 showed the effect of exosome processing time (24, 48, and 72 h) on cell viability. (B, C) Quantitative bar charts of the flow cytometry data, showing the percentage of CD235a + and CD71 + cells in the K562 population, respectively. (D, E) Representative flow cytometry gating plots showing the expression of erythroid differentiation markers CD235a and CD71 on the surface of K562 cells after treatment with exosomes from ANTXR1-overexpressing or silenced BMSCs. (F) Western blot analysis of GATA1 and ALAS2 protein expression. (G, H) Quantification of the relative protein expression of GATA1 and ALAS2, respectively. (I, J)Relative mRNA expression of GATA1 and ALAS2 determined by qRT-PCR. (K) Quantification of the percentage of benzidine-positive cells. Data are presented as mean ± SD. Statistical significance is indicated as follows: *p < 0.05, **p < 0.01.***p < 0.001. Exosomal ANTXR1 suppresses apoptosis and the TLR4/MYD88/NF-κB pathway Given that cellular differentiation is linked with apoptosis, the pro-apoptotic effects of exosomal ANTXR1 on K562 cells were assessed. A significant increase in the proportion of apoptotic cells was observed following treatment with sh-ANTXR1 exo. Conversely, the apoptosis rate was reduced by OE-ANTXR1 exo (Fig. 3A,B). Since inflammatory signaling is also a critical regulator of erythropoiesis, the involvement of the TLR4/MYD88/NF-κB pathway was next investigated. Indeed, activation of this pathway was significantly promoted by sh-ANTXR1 exo, as demonstrated by the upregulation of TLR4 and MYD88 protein levels and a marked increase in p65 phosphorylation. In contrast, this signaling axis was suppressed in cells treated with OE-ANTXR1 exo (Fig. 3C–G). We labeled both the exosomes and the ANTXR1 protein simultaneously. Quantitative flow cytometry analysis revealed that the uptake rate in the BMSCs exosome group reached 75%, significantly higher than the Control group (p < 0.001). This confirms that the exosomes were effectively taken up by the recipient cells. Additionally, ANTXR1 protein expression was detected in red blood cells (Fig. 3H). These results indicate that red blood cells can take up exosomes carrying the ANTXR1 protein. In CD34 + cells, exosomes containing sh-ANTXR1 also induce apoptosis and activate the TLR4/MYD88/NF-κB signaling pathway (see Supplementary Fig. 2). Fig. 3ANTXR1 promotes cell differentiation by regulating apoptosis and inflammation in K562 cells. (A) Flow cytometry detecting the apoptosis rate of K562 cells. (B) Quantitative bar chart of the K562 cell apoptosis rate. (C) Western blot images showing the protein expression in the TLR4/MYD88/NF-κB signaling pathway. (D-G) Bar charts quantifying the protein levels of TLR4, MyD88, p-p65, and p65. (H) Flow cytometry analysis of exosome uptake by cells and the ANTXR1 protein. Data are presented as mean ± SD. Statistical significance is indicated as follows: *p < 0.05, **p < 0.01.***p < 0.001. ANTXR1 promotes cell differentiation by regulating apoptosis and inflammation in K562 cells. (A) Flow cytometry detecting the apoptosis rate of K562 cells. (B) Quantitative bar chart of the K562 cell apoptosis rate. (C) Western blot images showing the protein expression in the TLR4/MYD88/NF-κB signaling pathway. (D-G) Bar charts quantifying the protein levels of TLR4, MyD88, p-p65, and p65. (H) Flow cytometry analysis of exosome uptake by cells and the ANTXR1 protein. Data are presented as mean ± SD. Statistical significance is indicated as follows: *p < 0.05, **p < 0.01.***p < 0.001. The pro-differentiative effect of ANTXR1 silencing is dependent on TLR4 signaling To further validate our hypothesis that the pro-erythroid effects of sh-ANTXR1 exo are mediated through TLR4 activation, K562 cells were treated with sh-ANTXR1 exo in the presence or absence of the TLR4 inhibitor, Stepharine. First, CCK8 assay showed that treating with sh-ANTXR1 exo caused a significant, time-dependent decrease in cell viability, an outcome indicative of cellular differentiation. Notably, co-treatment with the TLR4 inhibitor significantly rescued cell viability (Fig. 4A). Flow cytometry analysis further confirmed this dependency. While sh-ANTXR1 exo treatment markedly increased the percentage of cells expressing the erythroid markers CD235a and CD71, the addition of the TLR4 inhibitor significantly attenuated this increase (Fig. 4B–E). Subsequently, the effect on key erythroid transcription factors was examined. As expected, exosomes from sh-ANTXR1 exo treatment significantly upregulated GATA1 and ALAS2 at both the protein and mRNA levels. However, the TLR4 inhibitor blunted this sh-ANTXR1 exo induced upregulation (Fig. 4F–J). Finally, benzidine staining was used to functionally confirm these findings by assessing hemoglobin synthesis (Fig. 4K). The results demonstrated that inhibiting TLR4 could reverse the increase in hemoglobin production induced by sh-ANTXR1 exo, as evidenced by a marked reduction in benzidine-positive cells in the co-treatment group. The same results were observed in CD34 + cells, as shown in Supplementary Fig. 3. Fig. 4Inhibition of TLR4 attenuates the pro-erythroid differentiation effect of ANTXR1 silencing. (A) Cell viability of K562 cells, as assessed by a CCK8 assay, following treatment with exosomes from shANTXR1 exo with or without a TLR4 inhibitor. (B, C) Quantitative bar charts showing the percentage of CD235a + and CD71 + cells in the K562 population, based on flow cytometry data. (D, E) Representative flow cytometry gating plots for the erythroid markers CD235a and CD71. (F) Representative Western Blot images showing the protein expression of the erythroid-related proteins GATA1 and ALAS2. (G, H) Quantitative analysis of GATA1 and ALAS2 protein expression levels. (I, J) Relative mRNA expression of GATA1 and ALAS2 as determined by qRT-PCR. (K) Representative images of benzidine staining, showing hemoglobin synthesis in K562 cells under different treatment conditions. Statistical significance is indicated as follows: *p < 0.05, **p < 0.01.***p < 0.001. Inhibition of TLR4 attenuates the pro-erythroid differentiation effect of ANTXR1 silencing. (A) Cell viability of K562 cells, as assessed by a CCK8 assay, following treatment with exosomes from shANTXR1 exo with or without a TLR4 inhibitor. (B, C) Quantitative bar charts showing the percentage of CD235a + and CD71 + cells in the K562 population, based on flow cytometry data. (D, E) Representative flow cytometry gating plots for the erythroid markers CD235a and CD71. (F) Representative Western Blot images showing the protein expression of the erythroid-related proteins GATA1 and ALAS2. (G, H) Quantitative analysis of GATA1 and ALAS2 protein expression levels. (I, J) Relative mRNA expression of GATA1 and ALAS2 as determined by qRT-PCR. (K) Representative images of benzidine staining, showing hemoglobin synthesis in K562 cells under different treatment conditions. Statistical significance is indicated as follows: *p < 0.05, **p < 0.01.***p < 0.001. Activation of the TLR4/MyD88/NF-κB pathway by sh-ANTXR1 exosomes To further confirm that exosomes carrying ANTXR1 regulate erythroid differentiation by modulating the TLR4/MyD88/NF-κB signaling pathway, the expression of key proteins within this cascade was assessed. The results showed that, compared to the sh-NC BMSCs exo group, the protein levels of TLR4, MyD88, NF-κB, and p-p65 were significantly upregulated by treatment with sh-ANTXR1 exo. Importantly, the expression of these proteins was markedly downregulated by co-treatment with a TLR4 inhibitor, demonstrating that the TLR4/MyD88/NF-κB pathway is activated by sh-ANTXR1 exo (Fig. 5A–E). To validate these findings, the expression of downstream cytokines regulated by this pathway was examined. Consistent with the protein expression trends, the levels of IL-1β, IL-10, and TNF-α were similarly elevated by sh-ANTXR1 exo and suppressed by the TLR4 inhibitor (Fig. 5F–H). Given that TGF-β is a potent inhibitor of hematopoiesis, its expression was also investigated. It was found that sh-ANTXR1 exo significantly inhibited TGF-β expression, and this inhibition was partially rescued by the addition of the TLR4 inhibitor (Fig. 5I). Finally, to assess the functional consequences of this pathway activation, apoptosis was measured by flow cytometry. The results indicated that the apoptotic rate of K562 cells was significantly increased by sh-ANTXR1 exo compared to the sh-NC BMSCs exo group. This pro-apoptotic effect was significantly diminished by the TLR4 inhibitor, linking TLR4 pathway activation to cellular fate decisions during differentiation (Fig. 5J,K). Similarly, this effect can also be observed in CD34 + cells (Supplementary Fig. 4). Fig. 5The TLR4/MyD88/NF-κB pathway is modulated by ANTXR1-deficient exosomes. (A) Representative Western Blot images showing the expression of proteins related to the TLR4/MyD88/NF-κB pathway in K562 cells. (B-E) Quantitative analysis of the protein levels of TLR4, MyD88, NF-κB, and the ratio of p-p65 to total p65. β-actin was used as a loading control. (F-I) ELISA results showing the levels of the cytokines IL-1β, IL-10, and TNF-α, and the hematopoietic inhibitory factor TGF-β. (J, K) Representative flow cytometry plots and corresponding quantification of apoptosis in K562 cells following treatment with ANTXR1-silenced exosomes with or without a TLR4 inhibitor. Statistical significance is indicated as follows: *p < 0.05, **p < 0.01.***p < 0.001. The TLR4/MyD88/NF-κB pathway is modulated by ANTXR1-deficient exosomes. (A) Representative Western Blot images showing the expression of proteins related to the TLR4/MyD88/NF-κB pathway in K562 cells. (B-E) Quantitative analysis of the protein levels of TLR4, MyD88, NF-κB, and the ratio of p-p65 to total p65. β-actin was used as a loading control. (F-I) ELISA results showing the levels of the cytokines IL-1β, IL-10, and TNF-α, and the hematopoietic inhibitory factor TGF-β. (J, K) Representative flow cytometry plots and corresponding quantification of apoptosis in K562 cells following treatment with ANTXR1-silenced exosomes with or without a TLR4 inhibitor. Statistical significance is indicated as follows: *p < 0.05, **p < 0.01.***p < 0.001. Validation of the effects of sh-ANTXR1 exosomes using a TLR4 agonist We employed a TLR4 agonist (MPLA) to validate the effects of sh-ANTXR1 exosomes on erythrocyte phenotype and signaling pathways. The results indicated that co-treatment with sh-ANTXR1 exosomes and MPLA further reduced erythrocyte viability (Fig. 6A). Consistent with the findings in Fig. 4, sh-ANTXR1 exosomes increased the levels of ALAS2 and GATA1 proteins, and MPLA alone also elevated protein expression. However, co-treatment resulted in an even greater increase in the levels of ALAS2 and GATA1 proteins (Fig. 6B–C). Subsequently, flow cytometry was employed to assess the differentiation and apoptosis levels of K562 cells. The results showed that when sh-ANTXR1 exosomes were used alone, co-treatment with MPLA promoted erythrocyte differentiation, as evidenced by increased levels of CD235a and CD71 (Fig. 6D–E), while also promoting erythrocyte apoptosis (Fig. 6F). The study further examined the effects of TLR4 agonists on the TLR4/MyD88/NF-κB signaling pathway. The findings revealed that sh-ANTXR1-containing exosomes can activate the TLR4/MyD88/NF-κB signaling pathway, and that co-treatment with MPLA enhances this activation (Fig. 6G). Concurrently, Co-IP analysis confirmed a targeted interaction between ANTXR1 and TLR4 (Fig. 6H). These results suggest that the promotion of erythrocyte differentiation by sh-ANTXR1-derived exosomes may be linked to the activation of the TLR4/MyD88/NF-κB signaling pathway. Fig. 6Validation of the Effects of sh-ANTXR1 Exosomes Using a TLR4 Agonist. (A) CCK-8 assay to assess cell viability. (B–C) Western blot analysis of ALAS2 and GATA1 protein expression in K562 cells. (D–E) Flow cytometry analysis of K562 cell differentiation. (F) Flow cytometry analysis of apoptosis. (G) Representative Western blot images showing the expression of proteins associated with the TLR4/MyD88/NF-κB pathway in K562 cells. (H) Co-immunoprecipitation (Co-IP) validation of the interaction between TLR4 and ANTR1. Statistical significance is indicated as follows: *p < 0.05, **p < 0.01.***p < 0.001. Validation of the Effects of sh-ANTXR1 Exosomes Using a TLR4 Agonist. (A) CCK-8 assay to assess cell viability. (B–C) Western blot analysis of ALAS2 and GATA1 protein expression in K562 cells. (D–E) Flow cytometry analysis of K562 cell differentiation. (F) Flow cytometry analysis of apoptosis. (G) Representative Western blot images showing the expression of proteins associated with the TLR4/MyD88/NF-κB pathway in K562 cells. (H) Co-immunoprecipitation (Co-IP) validation of the interaction between TLR4 and ANTR1. Statistical significance is indicated as follows: *p < 0.05, **p < 0.01.***p < 0.001. Discussion Aplastic anemia is pathologically defined by bone marrow failure, where hematopoietic tissue is replaced by fat, leading to severe anemia, infection, and bleeding risks26,27. BMSCs, key stromal cells, are known to support hematopoietic homeostasis28. Accordingly, transplantation of healthy BMSCs or their extracellular vesicles has been shown to rescue hematopoiesis in AA mouse models, making them a therapeutic focus28,29. However, the role of the microenvironment in disease is complex, and pathological BMSCs can also secrete factors that worsen hematopoietic failure. Our findings reveal a potential alternative function, suggesting that BMSCs can negatively regulate hematopoiesis by releasing exosomes carrying inhibitory molecules. We propose that exosomal ANTXR1 is a key mediator of this functional shift. Exosomes are nanoscale vesicles that mediate intercellular communication by transferring bioactive cargo, playing key roles in health and disease30. BMSC-derived exosomes are known to modulate target cell function by delivering such cargo31. Here, we identify ANTXR1 as a novel cargo protein in BMSC exosomes. We first established and validated BMSC cultures. Using lentiviral transduction, we generated OE-ANTXR1 and sh-ANTXR1 BMSC lines. Exosomes isolated from the supernatant of these modified cells showed ANTXR1 protein levels that mirrored those in the parent cells. These findings demonstrate that BMSCs can remotely regulate neighboring hematopoietic progenitor cells by delivering ANTXR1 via exosomes within the bone marrow microenvironment. The bone marrow microenvironment in AA is characterized by persistent immune activation, an imbalance of inflammatory factors, increased oxidative stress, and functional remodeling of stromal cells. Previous studies have indicated that persistently elevated levels of inflammatory factors, such as IFN-γ and TNF-α, in the bone marrow of AA patients can damage bone marrow-derived mesenchymal stem cells (BMSCs). This damage leads BMSCs to exert paracrine effects that influence the proliferation and differentiation of hematopoietic stem cells32,33. As a cell-surface protein involved in cell adhesion, ANTXR1 plays a crucial role in the mechanotransduction of BMSCs19. We therefore hypothesize that abnormal ANTXR1 expression may arise from BMSC adaptation to inflammation and injury. In AA, changes in the microenvironment, such as chronic inflammatory stimulation, may lead to abnormal alterations in ANTXR1 in BMSCs, which are subsequently transmitted to hematopoietic cells via the exosome pathway. From a regulatory perspective, ANTXR1 expression is likely influenced by multiple factors. Studies have shown that inhibiting ANTXR1 expression in fibroblasts promotes inflammatory responses34, suggesting that these responses may contribute to ANTXR1 alterations. Furthermore, in colorectal cancer cells, acetylation of ANTXR1 enhances its stability35, indicating that epigenetic modifications may also play a role in regulating ANTXR1. Thus, changes in ANTXR1 expression derived from BMSCs in AA may reflect the combined effects of the pathological microenvironment on the functional remodeling of mesenchymal cells. Erythropoiesis is a tightly controlled process of cellular proliferation and differentiation36. Previous work showed that intracellular ANTXR1 is a negative regulator of erythroid differentiation; its overexpression in progenitor cells like K562 inhibits this process and downregulates the key factors GATA1 and ALAS2, while its knockdown has the opposite effect37. Our study proposes a novel exosome-based regulatory model for this function. In vitro, we found that exosomes from ANTXR1-overexpressing (OE-ANTXR1) BMSCs significantly reduced erythroid colony formation. These exosomes also suppressed the expression of erythroid markers (CD235a, CD71) and key regulatory genes (GATA1, ALAS2) in target cells. Conversely, exosomes from ANTXR1-knockdown (sh-ANTXR1) BMSCs promoted erythroid differentiation. These findings are consistent with the known intracellular role of ANTXR1 and confirm that it retains its inhibitory function when delivered via exosomes. To clarify the relationship between ANTXR1 in BMSC-derived exosomes and erythroid differentiation phenotypes, we focused on the TLR4/MyD88/NF-κB signaling axis. In an in vitro model, we found that exosomes derived from cells with low ANTXR1 expression (sh-ANTXR1 exo) displayed upregulated TLR4 and MyD88 expression, along with increased p65 phosphorylation, compared to control exosomes. Concurrently, markers associated with erythroid differentiation increased, while cell proliferation decreased and apoptosis increased. Additionally, treatment with a TLR4 inhibitor significantly reduced the phenotypic and molecular changes linked to erythrocyte differentiation, whereas treatment with an agonist further enhanced these effects. This indicates that the observed phenotype is associated with TLR4 signaling activation and is partially dependent on the TLR4 pathway. Consistent with previous studies38, ineffective erythrocyte differentiation leads to increased apoptosis, exacerbating anemia. As a classic inflammatory pathway, activation of the TLR4/MyD88/NF-κB axis inhibits erythrocyte proliferation and promotes apoptosis39. Given our observation of a physical interaction between ANTXR1 and TLR4, we propose that exosomes derived from sh-ANTXR1 may induce erythrocyte dysdifferentiation and apoptosis by activating the TLR4/MyD88/NF-κB axis, thus worsening anemia. However, since BMSC-derived exosomes contain various bioactive components, they may influence recipient cells through multiple targets and pathways. Therefore, ANTXR1 may be one of the factors contributing to BMSC exosome-mediated erythrocyte phenotypic changes, and this process may be linked to the TLR4/MyD88/NF-κB axis. This study has the following limitations: (1) Due to the complex composition of exosomes, the current data only support the conclusion that “ANTXR1 in exosomes is one of the key influencing factors,” which is insufficient to identify it as a direct, decisive molecule. Future studies will conduct functional rescue experiments to determine the direct role of ANTXR1. (2) The mechanistic understanding is not sufficiently in-depth. We demonstrated that the phenotypic changes induced by sh-ANTXR1-containing exosomes are associated with TLR4; however, this does not prove that the effect is entirely dependent on the TLR4/MyD88/NF-κB axis. Further mechanistic studies are required. (3) This study primarily relied on in vitro cellular models (K562 and umbilical cord blood CD34⁺ cells) for validation and has not yet undergone in vivo or clinical validation in animal models of AA or clinical samples from AA patients. Future studies should validate the pathological mechanisms of AA and potential intervention targets using animal disease models. In conclusion, we have preliminarily identified a functional effect of BMSC-derived exosomal ANTXR1 on erythroid differentiation in vitro. We confirmed that ANTXR1 is an exosomal cargo protein that may inhibit erythroid progenitors, potentially correlating with the activation of the TLR4/MyD88/NF-κB pathway. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2